Resources for Modern Methods to Detect Prostate Cancer
By Ronald Wheeler, MD
Vol. 4, Issue 2
Pp. 31-34
1. Gaylis, F.D., Lin, D.W., Ignatoff, J.M., Amling, C.L., etal.: Prostate cancer in men using testosterone supplementation. J Urol, 174: 534-538, 2005
2. Wheeler, R.E., Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution). J Clin Interventions in Aging, 2 (1): 153-161, 2007
3. Chan, J.M., Gann P.H., Giovannucci, E.L.: Role of diet in prostate cancer development and progression. J Clin Oncol, 23: 81, 52-60, 2005
4. Coussens, L.M., Werb, Z.: Inflammation and cancer. Nature, 420: 860-867, 2002
5. Margolis, S., Carter, H.B., Prostate disorders. The Johns Hopkins White Paper. Baltimore: Johns Hopkins, P 28, 2002
6. Nelson, W.G., DeMarzo, A.M., DeWeese, T.L., etal.: The role of inflammation in the pathogenesis of prostate cancer. J Urol, 172: S6-S12, 2004
7. Ornish, D., Weidner, D, Fair, W.R., etal.: Intensive lifestyle changes may affect the progression of prostate cancer. J Urol, 174: 1065-1070, 2005
8. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients. Endocr Pract, 8: 440-456, 2002
9. Mulligan, T., Frick, M.F., Zuraw, Q.C., etal.: Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract, 60 (7): 762-769, 2006
10. Loughlin, K.R., Richie, J.P.: Prostate cancer after exogenous testosterone treatment for impotence. J Urol, 157: 1845, 1997
11. Curran, M.J., Birhrle, W.: Dramatic rise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology, 53: 423, 1999
12. Morentaler, A., Bruning, C.O., DeWolf, W.C.: Occult prostate cancer in men with low serum testosterone levels. JAMA, 276: 1904, 1996
13. Rhoden, E. L., Morgentaler, A.: Risks of testosterone replacement therapy and recommendations for monitoring. N Engl J Med, 350: 482, 2004
14. Bhasin, S., Singh, A.B., Mac, R.P., etal.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl, 24: 299, 2003
15. Livermore, C.T., Blazer, D.G.: Testosterone and aging: Clinical research directions. Institute of Medicine of the National Academies Press, 2004
16. Bhasin, S., Buckwalter, J.G.: Testosterone supplementation in older men: a rational idea whose time has not come yet. J Androl, 22: 718, 2001
17. Koppie,T.M., Grady B.P., Shinohara, K.: Rectal wall recurrence of prostatic adenocarcinoma. Journal of Urology, 168: 2120, 2002
18. Moul, J.W., Bauer, J.J., Srivastava, S., etal.: Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after a needle biopsy and radical prostatectomy: molecular correlation. Urology, 51: 158, 1998
19. Haddad, F.S., Somsin, A.A.: Seeding and perineal implantation of prostatic cancer in the track of the biopsy needle: three case reports and a review of the literature. J Surg Oncol, 35: 184, 1987
20. Bastacky, S.S., Walsh, P.C., Epstein, J.I.: Needle biopsy associated tumor tracking of adenocarcinoma of the prostate. J Urology, 145: 1003, 1991
|